gilteritinib + atezolizumab
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Trial Timeline
Jun 19, 2019 → Jun 15, 2021
NCT ID
NCT03730012About gilteritinib + atezolizumab
gilteritinib + atezolizumab is a phase 1/2 stage product being developed by Astellas Pharma for Acute Myeloid Leukemia (AML). The current trial status is completed. This product is registered under clinical trial identifier NCT03730012. Target conditions include Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia (AML) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03730012 | Phase 1/2 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)